Syndax Q4 2023 Earnings Report
Key Takeaways
Syndax Pharmaceuticals reported a net loss attributable to common stockholders of $72.5 million, or $1.00 per share, for the three months ended December 31, 2023. The company's cash and cash equivalents are expected to provide runway through 2026.
BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024.
NDA for revumenib in R/R KMT2Ar acute leukemia submitted under FDA’s RTOR program; PDUFA date assignment expected in 1Q24.
Enrollment in AUGMENT-101 mNPM1 patient cohort expected to complete in late 1Q/early 2Q; topline data in 4Q24.
$600 million in cash and cash equivalents expected to provide runway through 2026.
Syndax
Syndax
Forward Guidance
The Company expects research and development expenses to be $56 to $62 million and total operating expenses to be $82 to $88 million for the first quarter of 2024. For the full year of 2024, the Company expects research and development expenses to be $240 to $260 million and total operating expenses to be $355 to $375 million, which includes an estimated $43 million in non-cash stock compensation expense. The Company believes that it has sufficient cash runway to fund its research, clinical development and commercial operations through 2026.